Literature DB >> 31911863

SPOP targets oncogenic protein ZBTB3 for destruction to suppress endometrial cancer.

Xiaofeng Jin1, Jian Wang1, Qian Li1, Hui Zhuang1, Jianye Yang1, Zihan Lin1, Ting Lin1, Zeheng Lv2, Liliang Shen3, Chunhong Yan4, Jingfei Zheng4, Jie Zhu5, Zhaohui Gong1, Chenji Wang6, Kun Gao2.   

Abstract

Dysregulation of the ubiquitin-proteasome pathway is closely associated with cancer initiation and progression. SPOP is an adapter protein of the CUL3-based E3 ubiquitin ligase complexes. Several whole genome/exome sequencing studies on endometrial cancers (ECs) revealed that the SPOP gene is frequently mutated. However, how SPOP mutations contribute to EC remains poorly understood. In this study, transcription factor ZBTB3 was identified as a proteolytic substrate for the SPOP-CUL3-RBX1 E3 ubiquitin ligase complex. SPOP specifically recognizes two Ser/Thr (S/T)-rich degrons located in ZBTB3 and triggers the degradation of ZBTB3 via the ubiquitin-proteasome pathway. By contrast, EC-associated SPOP mutants are defective in regulating ZBTB3 stability. SPOP inactivation promotes endometrial cell proliferation, migration, and invasion partly through ZBTB3 accumulation. Sonic hedgehog (SHH) was found to be a transcriptional target of ZBTB3. SPOP inactivation leads to ZBTB3-dependent SHH upregulation in EC cells. RUSKI-43, a small molecule inhibitor of SHH, suppresses cell proliferation, migration, and invasion in SPOP-depleted or EC-associated SPOP mutant-overexpressed EC cells. Our data indicate that pharmacological inhibition of SHH represents a possible treatment strategy for SPOP-mutated ECs. AJCR
Copyright © 2019.

Entities:  

Keywords:  SPOP; ZBTB3; endometrial cancer; sonic hedgehog; ubiquitination

Year:  2019        PMID: 31911863      PMCID: PMC6943363     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  37 in total

1.  Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.

Authors:  Linli Zhang; Shan Peng; Xiangpeng Dai; Wenjian Gan; Xin Nie; Wenyi Wei; Guoqing Hu; Jianping Guo
Journal:  Cancer Lett       Date:  2017-01-13       Impact factor: 8.679

2.  Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.

Authors:  Chuandong Geng; Kimal Rajapakshe; Shrijal S Shah; John Shou; Vijay Kumar Eedunuri; Christopher Foley; Warren Fiskus; Mahitha Rajendran; Sue Anne Chew; Martin Zimmermann; Richard Bond; Bin He; Cristian Coarfa; Nicholas Mitsiades
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

3.  International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013.

Authors:  Joannie Lortet-Tieulent; Jacques Ferlay; Freddie Bray; Ahmedin Jemal
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

4.  Spop promotes skeletal development and homeostasis by positively regulating Ihh signaling.

Authors:  Hongchen Cai; Aimin Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-05       Impact factor: 11.205

5.  Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.

Authors:  Gregory Sutton; Janice H Axelrod; Brian N Bundy; Tapan Roy; Howard D Homesley; John H Malfetano; Borys R Mychalczak; Mary E King
Journal:  Gynecol Oncol       Date:  2005-06       Impact factor: 5.482

6.  Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

Authors:  Siming Zhao; Murim Choi; John D Overton; Stefania Bellone; Dana M Roque; Emiliano Cocco; Federica Guzzo; Diana P English; Joyce Varughese; Sara Gasparrini; Ileana Bortolomai; Natalia Buza; Pei Hui; Maysa Abu-Khalaf; Antonella Ravaggi; Eliana Bignotti; Elisabetta Bandiera; Chiara Romani; Paola Todeschini; Renata Tassi; Laura Zanotti; Luisa Carrara; Sergio Pecorelli; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Amy L Stiegler; Shrikant Mane; Titus J Boggon; Joseph Schlessinger; Richard P Lifton; Alessandro D Santin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

7.  Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

Authors:  Xiangpeng Dai; Wenjian Gan; Xiaoning Li; Shangqian Wang; Wei Zhang; Ling Huang; Shengwu Liu; Qing Zhong; Jianping Guo; Jinfang Zhang; Ting Chen; Kouhei Shimizu; Francisco Beca; Mirjam Blattner; Divya Vasudevan; Dennis L Buckley; Jun Qi; Lorenz Buser; Pengda Liu; Hiroyuki Inuzuka; Andrew H Beck; Liewei Wang; Peter J Wild; Levi A Garraway; Mark A Rubin; Christopher E Barbieri; Kwok-Kin Wong; Senthil K Muthuswamy; Jiaoti Huang; Yu Chen; James E Bradner; Wenyi Wei
Journal:  Nat Med       Date:  2017-08-14       Impact factor: 53.440

8.  Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases.

Authors:  Min Zhuang; Matthew F Calabrese; Jiang Liu; M Brett Waddell; Amanda Nourse; Michal Hammel; Darcie J Miller; Helen Walden; David M Duda; Steven N Seyedin; Timothy Hoggard; J Wade Harper; Kevin P White; Brenda A Schulman
Journal:  Mol Cell       Date:  2009-10-09       Impact factor: 17.970

9.  Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.

Authors:  Matthieu Le Gallo; Andrea J O'Hara; Meghan L Rudd; Mary Ellen Urick; Nancy F Hansen; Nigel J O'Neil; Jessica C Price; Suiyuan Zhang; Bryant M England; Andrew K Godwin; Dennis C Sgroi; Philip Hieter; James C Mullikin; Maria J Merino; Daphne W Bell
Journal:  Nat Genet       Date:  2012-10-28       Impact factor: 38.330

10.  Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover.

Authors:  P Zhang; K Gao; X Jin; J Ma; J Peng; R Wumaier; Y Tang; Y Zhang; J An; Q Yan; Y Dong; H Huang; L Yu; C Wang
Journal:  Cell Death Dis       Date:  2015-03-12       Impact factor: 8.469

View more
  2 in total

1.  SPOP Inhibition of Endometrial Carcinoma and Its Clinicopathological Relationship.

Authors:  Qing Zhu; Guanghui Zhang; Mingyang Tang; Rumin Zheng; Huaiyong Gan
Journal:  Appl Bionics Biomech       Date:  2022-04-15       Impact factor: 1.664

2.  Regulator of cullins-1 (ROC1) negatively regulates the Gli2 regulator SUFU to activate the hedgehog pathway in bladder cancer.

Authors:  W Wang; J Qiu; P Qu; H Chen; J Lan; H Chen; L Li; M Gu
Journal:  Cancer Cell Int       Date:  2021-01-26       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.